Skip to content

Study · Randomized controlled trial · 2011

2 results

Divergent effects of two different doses of intranasal oxytocin on facial affect discrimination in schizophrenic patients with and without polydipsia.

Goldman MB, Gomes AM, Carter CS, Lee R

Psychopharmacology9 Feb 2011Cited by 92 (Europe PMC)

PMID21301811 (opens in a new tab)DOI10.1007/s00213-011-2193-8 (opens in a new tab)PepBankPUB-21301811
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In schizophrenic patients with and without polydipsia, 10 IU intranasal oxytocin reduced emotion recognition because patients identified emotions more often regardless of whether they were displayed.

    In plain wordsIn people with schizophrenia, a lower nasal oxytocin dose made emotion recognition worse in both patient groups.

    Peptide
    Oxytocin
    Outcome
    DecreaseEmotion recognition after 10 IU in schizophrenic patients
    Study

    n: not reported in source

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    10 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    Emotion recognition fell in both patient groups following 10 IU of oxytocin due to an increased propensity to identify all emotions regardless of whether they were displayed.
    1 context sentence
    Summary · context
    Intranasal oxytocin (10 or 20 IU) and placebo were administered on three occasions to five polydipsic schizophrenic patients, eight nonpolydipsic patients, and 11 healthy controls.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In schizophrenic patients, 20 IU intranasal oxytocin improved emotion recognition in polydipsic relative to nonpolydipsic patients, mainly through divergent effects on the bias to identify fear in nonfearful faces.

    In plain wordsIn people with schizophrenia, a higher nasal oxytocin dose improved emotion recognition more in patients with polydipsia than in those without.

    Peptide
    Oxytocin
    Outcome
    IncreaseEmotion recognition after 20 IU in polydipsic versus nonpolydipsic patients
    Study

    n: not reported in source

    Comparator
    Nonpolydipsic patients
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    20 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    By contrast, emotion recognition improved following 20 IU in polydipsic relative to nonpolydipsic patients due primarily to divergent effects on the bias to identify fear in nonfearful faces.
    1 context sentence
    Summary · context
    Intranasal oxytocin (10 or 20 IU) and placebo were administered on three occasions to five polydipsic schizophrenic patients, eight nonpolydipsic patients, and 11 healthy controls.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.